Engineers Gate Manager LP Purchases New Stake in United Therapeutics Corporation $UTHR

Engineers Gate Manager LP acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,658 shares of the biotechnology company’s stock, valued at approximately $2,524,000.

Other hedge funds have also added to or reduced their stakes in the company. Arjuna Capital increased its stake in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares during the last quarter. Sage Rhino Capital LLC boosted its holdings in United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC boosted its holdings in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares during the period. Meeder Advisory Services Inc. grew its stake in United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance grew its stake in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 27 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

UTHR opened at $502.70 on Tuesday. The firm has a market capitalization of $21.56 billion, a P/E ratio of 17.99, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56. United Therapeutics Corporation has a one year low of $396.12 and a one year high of $609.35. The company has a fifty day moving average price of $520.02 and a 200-day moving average price of $540.96.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the company earned $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. On average, analysts expect that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $540.15, for a total transaction of $5,401,500.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,195,871.40. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $552.40, for a total transaction of $5,247,800.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,379,381.20. This trade represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 364,575 shares of company stock worth $191,659,133 over the last 90 days. Corporate insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada dropped their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.